Nordic Bioscience receives CLIA Certification and expands lab capabilities with ELF
April 7, 2025
Nordic Bioscience is now CLIA Certified—we are expanding towards diagnostics and clinical decision making, including ELF capabilities.
CLIA Certification
Our Nordic laboratory is now CLIA Certified—expanding towards diagnostics and clinical decision making. While we have always maintained CLIA standards, our clinical laboratory is now officially CLIA certified, in addition to our longstanding CAP accreditation.
This milestone reflects more than compliance. Our CLIA certification marks a meaningful step in our evolution towards supporting diagnostics and clinical decision-making with data that is truly fit for purpose.
Why this matters:
- Your biomarker results now come from a lab certified to meet all U.S. federal standards for clinical testing – ready to support diagnostic interpretation and real-world decisions.
- We are building capacity to support regulated studies, patient stratification and other health-impact applications with validated, compliant methods.
- Our commitment to quality is stronger than ever. Combined with CAP-accreditation, CLIA confirms our adherence to the most rigorous standard across the full testing process.
- Most importantly, we aim to be your trusted partner in precision medicine, ready to help navigate from discovery to decision.
We are enthusiastic about the possibilities this creates and we look forward to supporting our partners with enhanced capabilities and confidence.
ELF (Enhanced Liver Fibrosis) Test
In addition, our lab remains committed to long-term development, and now we’ve expanded our capabilities with the ELF (Enhanced Liver Fibrosis) Test.
This means that now are running ELF on the state-of-the-art Siemens Atellica platform, bringing speed, automation, and precision into routine fibrosis assessment. The ELF test provides a non-invasive composite score based on three circulating biomarkers (HA, PIIINP, and TIMP-1). The ELF score is a validated prognostic enrichment tool for predicting disease progression in patients with advanced fibrosis due to nonalcoholic steatohepatitis conditions such as MASLD or NAFLD.
What makes this even better?
- We only need 296 µL of sample—less than half of what many other labs require. This reduces the burden on patients and enables easier sampling in clinical or research settings.
- We offer next-level fibrosis insights by combining ELF testing with NordicPRO-C3™—a biomarker reflecting active fibrogenesis. Together, they provide a more comprehensive view of both fibrosis burden and dynamic activity.
We’re proud to support clinicians, researchers, and partners with high-quality, fit-for-purpose data—because informed decisions begin with trusted diagnostics.
Please reach out if you would like to explore what our CLIA certification or the ELF Test capability mean for your studies—we are excited for what is ahead, together.
Nordic Bioscience Presents Study on Neutrophil Activity as a Biomarker for Multiple Sclerosis
September 25, 2023
New research unveiling the Collagen Landscape in Cancer: Cancer-Associated Fibroblasts and Promising Biomarkers
September 21, 2023
PRESS RELEASE: Nordic Bioscience Secures Trademarks for Vital Biomarkers and Advanced Technology
September 20, 2023
Latest Publication Reveals Insights on Collagen Turnover Biomarkers in Hemophilia A Patients
September 18, 2023
Morten Karsdal, CEO of Nordic Bioscience, reflects on the PRO-C3 biomarker in tumor fibrosis FDA Letter of Support
June 20, 2023
PRESS RELEASE: Nordic Bioscience receives Letter of Support from the FDA for the PRO-C3 biomarker in tumor fibrosis
June 12, 2023
Morten Karsdal, CEO of Nordic Bioscience, receives The Arthur D. Little Nordic Life Science Award
April 14, 2023
Pliant Therapeutics publishes positive data from their INTEGRIS-IPF Phase 2a trial of bexotegrast featuring PRO-C3 biomarker
January 24, 2023
